CompletedNCT04352166
Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Addiction
Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 15, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Frances R Levin
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04352166
- Official title
Show the full official title
Randomized Controlled Trial of Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder Patients Using Fentanyl
Get this study by email
Recruitment & locations
CompletedNew York
Questions about this study
Who is behind this study?
The study sponsor is Frances R Levin.
Did this study involve medication?
Yes. The study involved medication, including extended-release buprenorphine (BXR) and sublingual buprenorphine (BSL).
Who was this study for?
Listed age limits: 18 years to 65 years.
